Brand Name Drug Negotiations Status
The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards:
- Canada’s Drug Agency (formerly CADTH)
- The Institut national d’excellence en santé et en services sociaux (INESSS) in Québec
For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by Canada’s Drug Agency and/or INESSS.
Together with our partners, we have designed the pCPA Temporary Access Process (pTAP) that will allow patients to have temporary access to some drugs earlier. More information is available on our pTAP webpage.
| Product | Manufacturer | Status | Indication |
|---|---|---|---|
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Under consideration for negotiation | For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR) |
| Venclexta (venetoclax) | AbbVie Corporation | Active Negotiation | for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion (in combination with Imbruvica) |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Rheumatoid Arthritis |
| Ayvakyt ( avapritinib) | Medison Pharma Canada Inc. | Under consideration for negotiation | Advanced Systemic Mastocytosis |
| Alecensaro (alectinib) | Hoffmann-La Roche Ltd. | Under consideration for negotiation |
adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). |
| Carvykti (ciltacabtagene autoleucel) | Janssen Inc. | Under consideration for negotiation | For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide. |
| Winrevair (sotatercept) | Merck Canada Inc. | Under consideration for negotiation | Pulmonary Arterial Hypertension (WHO group 1) |
| Wainua (eplontersen) | AstraZeneca Canada Inc. | Under consideration for negotiation | Polyneuropathy in hereditary transthyretin-mediated amyloidosis |
| Cabtreo (clindamycin plus benzoyl peroxide and adapalene) | Bausch Health, Canada Inc. | Under consideration for negotiation | Acne Vulgaris |
| Voydeya (danicopan) | Alexion Pharma GmbH | Under consideration for negotiation | Paroxysmal nocturnal hemoglobinuria (PNH) |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older |
| Libtayo (cemiplimab) | Regeneron | Active Negotiation | Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC |
| Libtayo (cemiplimab) | Regeneron | Active Negotiation | Basal cell carcinoma (BCC), locally advanced or metastatic, previously treated with a hedgehog pathway inhibitor |
| Tibsovo (ivosidenib) | Servier Canada Inc. | Under consideration for negotiation | In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Active Negotiation | In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded with an LOI | In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. |
| Osenvelt (denosumab) | Celltrion Healthcare Canada Ltd. | Active Negotiation | Multiple Indications |
| Stoboclo (denosumab) | Celltrion Healthcare Canada Ltd. | Active Negotiation | Multiple Indications |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI |
Neoadjuvant-adjuvant treatment of adult patients with stage III or stage IV melanoma |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Under consideration for negotiation | Hidradenitis Suppurativa |
| Olumiant (baricitinib) | Eli Lilly Canada Inc. | Under consideration for negotiation | Alopecia areata, severe |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Under consideration for negotiation | High-risk Hodgkins Lymphoma in the pediatric population, previously untreated (in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide); Advanced stage Hodgkins Lymphoma, previously untreated (in combination with doxorubicin, vinblastine, and dacarbazine) |
| Truqap (capivasertib) | AstraZeneca Canada Inc. | Active Negotiation | Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative) |
| Ixifi (Infliximab) | Pfizer Canada ULC | Active Negotiation | Multiple Indications |
| Vectibix (panitumumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC) patients with left-sided primary tumours that express wild-type RAS (In combination with chemotherapy) |
| Axberi/Axberi HP (enoxaparin sodium solution for injection) | Baxter Corporation | Active Negotiation | Thrombosis and cardiovascular conditions (prevention or treatment) |
| Leqvio (inclisiran) | Novartis Pharmaceuticals Canada Inc. | Under consideration for negotiation | Primary hypercholesterolemia |
| Vraylar (cariprazine) | AbbVie Corporation | Concluded with an LOI | Schizophrenia |
| Velsipity (Etrasimod) | Pfizer Canada ULC | Active Negotiation | Ulcerative Colitis |
| Veklury (remdesivir) | Gilead Sciences Canada Inc. | Under consideration for negotiation | COVID-19 in hospitalized patients |
| Veklury (remdesivir) | Gilead Sciences Canada Inc. | Under consideration for negotiation | COVID-19 in non-hospitalized patients |
| Apretude (cabotegravir) | ViiV Healthcare | Active Negotiation | HIV-1 infection, pre-exposure prophylaxis |
| Ebglyss (lebrikizumab) | Eli Lilly Canada Inc. | Under consideration for negotiation | Atopic dermatitis |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab) |
| Teva Naloxone Nasal Spray (naloxone hydrochloride) | Teva Canada Ltd. | Concluded with an LOI | Opioid overdose, known or suspected, for emergency use |
| Crysvita (burosumab) | Kyowa Kirin Canada, Inc. | Under consideration for negotiation | X-Linked Hypophosphatemia |
| Qulipta (atogepant) | AbbVie Corporation | Concluded with an LOI | Migraine, prevention |
| Tyenne (tocilizumab) | Fresenius Kabi Canada Ltd. | Active Negotiation | Multiple Indications |
| Maviret (glecaprevir/pibrentasvir granules) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C (Pediatric) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients, locally advanced unresectable or metastatic, HER2‑positive, first-line treatment in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by a validated test |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Biliary tract carcinoma (BTC) in adult patients, locally advanced unresectable or metastatic, in combination with chemotherapy |
| Rybrevant (amivantamab) | Janssen Inc. | Negotiations were not pursued | Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Crohn's disease |
| Repatha (evolocumab) | Amgen Canada Inc. | Under consideration for negotiation | Primary hyperlipidemia |
| Fulphila (pegfilgrastim) | BGP Pharma ULC | Active Negotiation | Febrile neutropenia in non-myeloid malignancies |
| Pexegra (pegfilgrastim) | Jamp Pharma Corporation | Active Negotiation | Febrile neutropenia in non-myeloid malignancies |
| Orgovyx (relugolix) | Sumitomo Pharma Canada, Inc. | Active Negotiation | Advanced prostate cancer |
| Elrexfio (elranatamab) | Pfizer Canada ULC | Active Negotiation | Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Stage IIB or IIC melanoma following complete resection, monotherapy for the adjuvant treatment of adult patients |
| Bimzelx (bimekizumab) | UCB Canada Inc. | Active Negotiation | Psoriatic Arthritis |
| Bimzelx (bimekizumab) | UCB Canada Inc. | Active Negotiation | Ankylosing spondylitis |
| Awiqli (insulin icodec) | Novo Nordisk Canada Inc. | Active Negotiation | Diabetes Mellitus, Type 2 |
| Epkinly (concluded with pTAP LOI) (epcoritamab) | AbbVie Corporation | Concluded with an LOI | Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) Relapsed or refractory , DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b), in adult patients, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy. |
| Tecentriq SC (atezolizumab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Multiple Indications |
| Jemperli (dostarlimab) | GlaxoSmithKline Inc. | Concluded with an LOI | Primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer in adult patients who are candidates for systemic therapy (in combination with carboplatin and paclitaxel) |
| Libtayo (cemiplimab) | Regeneron | Active Negotiation |
in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC |
| To be confirmed (ustekinumab) | Sandoz Canada Inc. | Active Negotiation | Multiple Indications |
| Wyost (denosumab 120 mg/1.7 mL) | Sandoz Canada Inc. | Concluded with an LOI | Multiple Indications |
| Epidiolex (cannabidiol) | Jazz Pharmaceuticals Canada Inc. | Active Negotiation | Seizures associated with Tuberous Sclerosis Complex (TSC) |
| Epidiolex (cannabidiol) | Jazz Pharmaceuticals Canada Inc. | Active Negotiation | Dravet Syndrome (DS) |
| Leqvio (inclisiran) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Primary hypercholesterolemia (non-familial and heterozygous familial) with atherosclerotic cardiovascular disease |
| Epidiolex (cannabidiol) | Jazz Pharmaceuticals Canada Inc. | Active Negotiation | Lennox-Gastaut Syndrome (LGS) |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Ulcerative Colitis |
| Hemgenix (etranacogene dezaparvovec) | CSL Behring Canada Inc. | Active Negotiation | Hemophilia B |
| Tecvayli (teclistamab) | Janssen Inc. | Active Negotiation | Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy |
| SIR-Spheres Y-90 resin microspheres (Yttrium-90 microspheres) | Sirtex Medical | Concluded with an LOI | Hepatocellular carcinoma (HCC) |
| TheraSphere Y-90 Glass Micropheres (Yttrium-90 microspheres) | Boston Scientific Corporation | Concluded without agreement | Hepatocellular carcinoma (HCC) |
| Eylea HD (aflibercept 8mg/0.07mL) | Bayer Inc. | Concluded with an LOI | Age-Related Macular Degeneration |
| Eylea HD (aflibercept 8mg/0.07mL) | Bayer Inc. | Concluded with an LOI | Diabetic Macular Edema |
| Uplizna (inebilizumab) | Horizon Therapeutics Canada | Active Negotiation | Neuromyelitis optica spectrum disorder (NMOSD) |
| Slynd (drospirenone) | Duchesnay Inc. | Concluded with an LOI | Contraceptive, oral |
| Ultomiris (ravulizumab) | Alexion Pharma GmbH | Active Negotiation | Neuromyelitis optica spectrum disorder (NMOSD) |
| Steqeyma (ustekinumab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Multiple Indications |
| Veklury (remdesivir) | Gilead Sciences Canada Inc. | Concluded with an LOI | COVID-19 |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | Metastatic colorectal cancer in adult patients who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. ( in combination with bevacizumab) |
| Myalepta (metreleptin) | Medison Pharma Canada Inc. | Active Negotiation | Leptin deficiency in lipodystrophy |
| Trecondyv (treosulfan) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | As part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies (In combination with fludarabine) |
| Suboxone (film) (buprenorphine and naloxone) | Indivior UK Limited | Concluded with an LOI | Opioid Dependence |
| Beqvez (fidanacogene elaparvovec) | Pfizer Canada ULC | Active Negotiation | Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74 |
| Rezurock (belumosudil) | Sanofi-Aventis Canada Inc. | Active Negotiation | Chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older, after failure of at least two prior lines of systemic therapy. |
| Paxlovid (nirmatrelvir/ritonavir) | Pfizer Canada ULC | Concluded with an LOI | Mild-to-moderate COVID-19, treatment |
| Columvi (glofitamab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy, in adult patients |
| Polivy (Polatuzumab Vedotin) | Hoffmann-La Roche Ltd. | Active Negotiation | Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)) |
| Opdualag (nivolumab and relatlimab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Unresectable or metastatic melanoma in adult and pediatric patients 12 years of age or older who have not received prior systemic therapy for unresectable or metastatic melanoma |
| Trodelvy (sacituzumab govitecan) | Gilead Sciences Canada Inc. | Active Negotiation | Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Metastatic castration-resistant prostate cancer (mCRPC) in adult patients (in combination with abiraterone and prednisone or prednisolone) |
| Akeega (niraparib abiraterone acetate) | Janssen Inc. | Concluded with an LOI | Deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC) in adult patients who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. (in combination with prednisone or prednisolone) |
| Amvuttra (vutrisiran) | Alnylam Netherlands B.V. | Concluded with an LOI | Hereditary transthyretin-mediated amyloidosis |
| Bylvay (odevixibat) | Medison Pharma Canada Inc. | Active Negotiation | Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC). |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Crohn's disease |
| Doptelet (avatrombopag) | Sobi Canada Inc. | Negotiations were not pursued | Chronic Immune Thrombocytopenia |
| Imbruvica (ibrutinib) | Janssen Inc. | Active Negotiation | Waldenström's Macroglobulinemia |
| Asparlas (calaspargase pegol) | Servier Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia (ALL) |
| Nucala (mepolizumab) | GlaxoSmithKline Inc. | Concluded with an LOI | Severe eosinophilic asthma, add-on maintenance treatment of in children (aged 6 years and older) |
| Pemazyre (pemigatinib) | Incyte Biosciences Canada Corporation | Active Negotiation | Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, Previously treated, in adults |
| Adtralza (tralokinumab) | LEO Pharma Inc. | Negotiations were not pursued | Atopic dermatitis |
| Vyvgart (efgartigimod alfa) | Argenx Canada Inc. | Active Negotiation | Generalized myasthenia gravis (gMG) |
| Rybelsus (semaglutide) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded with an LOI | Primary hyperlipidemia and mixed dyslipidemia |
| Ozempic (semaglutide) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Atriance (nelarabine) | Sandoz Canada Inc. | Negotiations were not pursued | Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis) |
| Octasa (mesalamine DR) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Ulcerative Colitis |
| Livmarli (maralixibat) | Mirum Pharmaceuticals Inc. | Active Negotiation | Alagille syndrome |
| Sogroya (somapacitan) | Novo Nordisk Canada Inc. | Negotiations were not pursued | Growth hormone deficiency |
| Evkeeza (evinacumab) | Ultragenyx Pharmaceutical Inc. | Active Negotiation | Homozygous Familial Hypercholesterolemia |
| Dupixent (dupilumab) | Sanofi Genzyme Canada | Active Negotiation | Atopic dermatitis, pediatrics |
| Yescarta (axicabtagene ciloleucel) | Gilead Sciences Canada Inc. | Concluded with an LOI | Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy |
| Imfinzi and Imjudo (durvalumab and tremelimumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Unresectable hepatocellular carcinoma (uHCC) in adult patients who require systemic therapy, first-line treatment |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded with an LOI | Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab) |
| Imbruvica (ibrutinib) | Janssen Inc. | Active Negotiation | In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion. |
| Lumakras (sotorasib) | Amgen Canada Inc. | Under consideration for negotiation | Advanced non-small cell lung cancer, KRAS G12C-mutated |
| Imcivree (setmelanotide) | Rhythm Pharmaceuticals, Inc. | Active Negotiation | Bardet-Biedl syndrome |
| Omvoh (mirikizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic fibrosis, F508del CFTR mutation, 2 years and older |
| Cablivi (caplacizumab) | Sanofi-Aventis Canada Inc. | Negotiations were not pursued | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| Onivyde (irinotecan liposome) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded without agreement | Metastatic Pancreatic Cancer |
| Kymriah (tisagenlecleucel) | Novartis Pharmaceuticals Canada Inc. | Active Negotiation | Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy |
| Xcopri (cenobamate) | Paladin Labs Inc. | Concluded without agreement | Epilepsy, partial-onset seizures |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Ulcerative Colitis |
| Brukinsa (zanubrutinib) | BeiGene, Ltd. | Concluded with an LOI | Chronic lymphocytic leukemia (CLL) in adult patients |
| Welireg (belzutifan) | Merck Canada Inc. | Concluded with an LOI | Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. |
| Jubbonti (denosumab 60 mg/mL) | Sandoz Canada Inc. | Concluded with an LOI | Multiple Indications |
| Mezera (mesalazine) | AVIR Pharma Inc. | Concluded with an LOI | Ulcerative Colitis |
| Zoryve (roflumilast) | Arcutis Biotherapeutics, Inc. | Concluded without agreement | Plaque psoriasis |
| Tavneos (avacopan) | Otsuka Canada Pharmaceutical Inc. | Active Negotiation | Antineutrophil cytoplasmic antibody-associated vasculitis |
| Sotyktu (deucravacitinib) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Ultomiris (ravulizumab) | Alexion Pharma GmbH | Negotiations were not pursued | Generalized Myasthenia Gravis, AChR antibody-positive |
| Tremfya (guselkumab) | Janssen Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Korsuva (difelikefalin) | Otsuka Canada Pharmaceutical Inc. | Negotiations were not pursued | Moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis |
| Wezlana (ustekinumab) | Amgen Canada Inc. | Concluded with an LOI | Multiple Indications |
| Enhertu (trastuzumab deruxtecan) | AstraZeneca Canada Inc. | Concluded with an LOI | Breast cancer, monotherapy for the treatment of adult patients, unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) |
| Vyalev (foslevodopa foscarbidopa) | AbbVie Corporation | Concluded with an LOI | Motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease. |
| Verquvo (vericiguat) | Bayer Inc. | Concluded with an LOI | Symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy |
| Qulipta (atogepant) | AbbVie Corporation | Concluded with an LOI | Episodic migraine in adults (prevention) |
| Sohonos (palovarotene) | Ipsen Biopharmaceuticals Canada, Inc. | Active Negotiation | Fibrodysplasia Ossificans Progressiva |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Ankylosing spondylitis |
| Koselugo (selumetinib) | Alexion Pharma GmbH | Concluded with an LOI | Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas |
| Rukobia (fostemsavir) | ViiV Healthcare | Concluded without agreement | HIV-1 infection, in combination with other antiretroviral agents, in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations |
| Skyrizi (risankizumab) | AbbVie Corporation | Concluded with an LOI | Moderately to severely active Crohn's disease in adults |
| Carvykti (ciltacabtagene autoleucel) | Janssen Inc. | Active Negotiation | Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment. |
| Jamteki (ustekinumab) | Jamp Pharma Corporation | Concluded with an LOI | Multiple Indications |
| Rylaze (crisantaspase recombinant) | Jazz Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase. |
| Lapelga (pegfilgrastim) | Apobiologix, a Division of Apotex Inc. | Concluded with an LOI | To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug. |
| Trurapi (insulin aspart) | Sanofi-Aventis Canada Inc. | Concluded with an LOI |
Diabetes mellitus in patients who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin), or continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion |
| Camzyos (mavacamten) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients. |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences Canada Inc. | Concluded with an LOI | Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Resectable Non-small cell lung cancer (tumours ≥4cm or node positive), neoadjuvant treatment of adult patients, when used in combination with platinum-doublet chemotherapy |
| Empaveli (pegcetacoplan) | Sobi Canada Inc. | Concluded with an LOI | Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor |
| Ranopto (ranibizumab) | Teva Canada Ltd. | Concluded with an LOI | Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy |
| Kerendia (finerenone) | Bayer Inc. | Concluded with an LOI | Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer, for adjuvant treatment of adult patients who have been treated with neoadjuvant or adjuvant chemotherapy |
| Pluvicto (lutetium vipivotide tetraxetan) | Advanced Accelerator Applications | Concluded without agreement | Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. |
| Rybrevant (amivantamab) | Janssen Inc. | Concluded without agreement | Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy |
| Ultomiris (ravulizumab) | Alexion Pharma GmbH | Concluded with an LOI | Atypical hemolytic uremic syndrome |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Concluded with an LOI | Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients |
| Orladeyo (berotralstat) | BioCryst Pharmaceuticals Inc. | Concluded with an LOI | Hereditary Angioedema |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer in adult patients, whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy. |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine-based chemotherapy |
| Yescarta (axicabtagene ciloleucel) | Gilead Sciences Canada Inc. | Concluded with an LOI | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy |
| Oxlumo (lumasiran) | Alnylam Netherlands B.V. | Concluded with an LOI | Primary Hyperoxaluria Type 1 |
| Dupixent (dupilumab) | Sanofi-Aventis Canada Inc. | Concluded with an LOI | Asthma |
| Dupixent (dupilumab) | Sanofi-Aventis Canada Inc. | Concluded with an LOI | Atopic dermatitis |
| Saphnelo (anifrolumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Systemic lupus erythematosus |
| Benlysta (belimumab) | GlaxoSmithKline Inc. | Concluded with an LOI | Active lupus nephritis |
| Ferriprox (deferiprone) | Chiesi Canada Corporation | Concluded without agreement | Transfusional iron overload due to sickle cell disease or other anemias |
| Ozurdex (dexamethasone) | AbbVie Corporation | Negotiations were not pursued | Diabetic Macular Edema |
| Beovu (brolucizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Diabetic Macular Edema |
| Nubeqa (Darolutamide) | Bayer Inc. | Concluded with an LOI | Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel |
| Dayvigo (lemborexant) | Eisai Limited | Concluded without agreement | Insomnia |
| Blood glucose test strips (blood glucose test strips) | Tykess Pharmaceuticals Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips ( blood glucose test strips) | Dex Medical Distribution Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Roche Diabetes Care, division of Hoffmann-La Roche Ltd. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Bionime USA Corporation | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test (in combination with chemotherapy) |
| Kimmtrak (tebentafusp) | Medison Pharma Canada Inc. | Concluded with an LOI | Unresectable or metastatic uveal melanoma in adult patients who are Human leukocyte antigen (HLA)-A*02:01-positive |
| Dificid (fidaxomicin) | Merck Canada Inc. | Concluded with an LOI | Clostridium difficile infection |
| Ruzurgi (Amifampridine) | Médunik Canada Inc. | Concluded with an LOI | Lambert-Eaton Myasthenic Syndrome (LEMS) |
| Radicava (edaravone) | Mitsubishi Tanabe Pharma Canada, Inc. | Concluded with an LOI | Amyotrophic Lateral Sclerosis (ALS) |
| Vyepti (eptinezumab) | Lundbeck Canada Inc. | Concluded with an LOI | Migraine, prevention |
| Uceris (budesonide) | Bausch Health, Canada Inc. | Concluded with an LOI | Active mild to moderate distal ulcerative colitis |
| Zepzelca (lurbinectedin) | Jazz Pharmaceuticals Canada Inc. | Negotiations were not pursued | Stage III or metastatic small cell lung cancer (SCLC) in adult patients who have progressed on or after platinum-containing therapy |
| Wakix (pitolisant hydrochloride) | Paladin Labs Inc. | Concluded without agreement | Excessive daytime sleepiness or cataplexy in adult patients with narcolepsy |
| Blood glucose test strips (blood glucose test strips) | Tremblay Harrison Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Sanofi-Aventis Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Nova Biomedical Canada Ltd. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Auto Control Medical Inc | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients |
| Zeposia (ozanimod) | Celgene Inc. | Concluded with an LOI | Ulcerative Colitis |
| Tremfya (guselkumab) | Janssen Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Nucala (mepolizumab) | GlaxoSmithKline Inc. | Concluded with an LOI | Severe chronic rhinosinusitis with nasal polyps |
| Tezspire (tezepelumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older |
| Xydalba (dalbavancin) | Paladin Labs Inc. | Concluded with an LOI | Acute bacterial skin and skin structure infections |
| Rymti (etanercept) | Lupin Pharma Canada Ltd. | Concluded with an LOI | Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis |
| Vraylar (cariprazine) | AbbVie Corporation | Negotiations were not pursued | Bipolar Disorder |
| Palynziq (pegvaliase) | BioMarin Pharmaceutical Inc. | Active Negotiation | Phenylketonuria |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients |
| Livtencity (maribavir) | Takeda Canada Inc. | Concluded with an LOI | Post-transplant Cytomegalovirus (CMV) Infection/disease |
| Rozlytrek (Entrectinib) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, in adult patients, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded with an LOI | Differentiated thyroid carcinoma (DTC), locally advanced or metastatic, in adult patients who are radioactive iodine-refractory (RAI-R) or ineligible, that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. | Active Negotiation | Adjunct to standard of care therapy for the treatment of chronic heart failure in adults |
| Vabysmo (faricimab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Diabetic Macular Edema |
| Minjuvi (tafasitamab) | Incyte Biosciences Canada Corporation | Concluded with an LOI | Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, including DLBCL arising from low grade lymphoma, in adult patients who are not eligible for autologous stem cell transplant (in combination with lenalidomide) |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease |
| Enhertu (trastuzumab deruxtecan) | AstraZeneca Canada Inc. | Concluded with an LOI | Unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adult patients who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Urothelial carcinoma (UC), monotherapy for the adjuvant treatment of adult patients who are at high risk of recurrence after undergoing radical resection of UC |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded with an LOI | Early breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20%,for the adjuvant treatment of adult patients (in combination with endocrine therapy) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Renal cell carcinoma (RCC), for adjuvant treatment of adult patients, at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions |
| Gavreto (pralsetinib) | Hoffmann-La Roche Ltd. | Concluded without agreement | Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), rearranged during transfection (RET) fusion-positive, in adult patients |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded with an LOI | Unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance |
| Wegovy (semaglutide) | Novo Nordisk Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute Graft-Versus-Host disease |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation (in combination with pembrolizumab) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima)) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients |
| Byooviz (ranibizumab) | Biogen Canada Inc. | Concluded with an LOI | Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy |
| Spinraza (nusinersen) | Biogen Canada Inc. | Negotiations were not pursued | Spinal Muscular Atrophy in adult patients over 18 years of age |
| Tecentriq (atezolizumab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition) |
| Tepmetko (tepotinib) | EMD Serono Canada, a division of EMD Inc. | Concluded with an LOI | Non-small cell lung cancer (NSCLC), locally advanced unresectable metastatic, harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, in adult patients |
| Jemperli (dostarlimab) | GlaxoSmithKline Inc. | Negotiations were not pursued | Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients |
| Cibinqo (abrocitinib) | Pfizer Canada ULC | Concluded with an LOI | Atopic Dermatitis, Moderate to Severe |
| Poteligeo (mogamulizumab) | Kyowa Kirin Canada, Inc. | Concluded with an LOI | Mycosis Fungoides (MF), Sézary Syndrome (SS) |
| Vabysmo (faricimab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Neovascular (Wet) Age-related Macular Degeneration (nAMD) |
| Vraylar (cariprazine) | AbbVie Corporation | Concluded with an LOI | Schizophrenia in Adults |
| Kirsty (insulin aspart) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Brukinsa (zanubrutinib) | BeiGene, Ltd. | Negotiations were not pursued | Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. |
| Xpovio (selinexor) | Forus Therapeutics Inc. | Concluded with an LOI | Multiple myeloma (MM) in adults with who have received at least one prior therapy (In combination with bortezomib (V) and dexamethasone (d)) |
| Scemblix (asciminib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients |
| Vegzelma (bevacizumab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma |
| Inqovi (decitabine-cedazuridine) | Taiho Pharma Canada Inc. | Concluded with an LOI | Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Graft-versus-host Disease |
| Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) | Amylyx Canada | Concluded with an LOI | Amyotrophic Lateral Sclerosis (ALS) |
| Breyanzi (lisocabtagene maraleucel) | Celgene Inc. | Concluded with an LOI | Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma |
| Nexviazyme (avalglucosidase alfa) | Sanofi-Aventis Canada Inc. | Concluded without agreement | Late-Onset Pompe Disease |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and/or lenvatinib |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima) |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | Advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC), in adult patients (In combination with pembrolizumab) |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Concluded with an LOI | Cardiomyopathy due to transthyretin-mediated amyloidosis |
| Firdapse (amifampridine phosphate) | KYE Pharmaceuticals Inc. | Concluded with an LOI | Lambert-Eaton Myasthenic Syndrome (LEMS) |
| pdp-Amlodipine (amlodipine) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Mild to moderate essential hypertension and management of chronic stable angina |
| Arazlo (tazarotene) | Bausch Health, Canada Inc. | Concluded with an LOI | Acne Vulgaris |
| Bryhali (halobetasol propionate) | Bausch Health, Canada Inc. | Concluded with an LOI | Corticosteroid-Responsive Dermatoses and The Topical Treatment of Plaque Psoriasis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Atopic dermatitis |
| Elonox and Elonox HP (enoxaparin sodium) | Fresenius Kabi Canada Ltd. | Concluded with an LOI | Thrombosis and cardiovascular conditions (prevention or treatment) |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older |
| Libtayo (cemiplimab) | Sanofi-Aventis Canada Inc. | Concluded without agreement | Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC |
| Osphena (ospemifene) | Duchesnay Inc. | Concluded without agreement | Dyspareunia and/or Vaginal Dryness |
| Nypozi (filgrastim) | Tanvex BioPharma USA, Inc. | Concluded with an LOI | Neutropenia in various indications (Prevention or treatment) |
| Semglee (Insulin Glargine) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | ForaCare Technology Canada, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Skymed Monitors Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | MediSure Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | LifeScan Canada ULC | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | I-Sens, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | BTNX Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Ascensia Diabetes Care | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Spirit Healthcare Group | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Blood glucose test strips (blood glucose test strips) | Abbott Diabetes Care | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Retevmo (selpercatinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients |
| Qinlock (ripretinib) | Medison Pharma Canada Inc. | Concluded with an LOI | Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib |
| Insulin pumps and pump supplies (insulin pumps and pump supplies) | Insulet Canada Corporation | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Ypsomed Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Medtronic Canada | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Intrarosa (prasterone) | Lupin Pharma Canada Ltd. | Concluded without agreement | Postmenopausal vulvovaginal atrophy |
| Tavalisse (fostamatinib) | Medison Pharma Canada Inc. | Negotiations were not pursued | Chronic Immune Thrombocytopenia |
| Bimzelx (bimekizumab) | UCB Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Pemazyre (pemigatinib) | Incyte Biosciences Canada Corporation | Negotiations were not pursued | Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) in adults with previously treated CCA with a FGFR2 fusion or other rearrangement |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Concluded without agreement | Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients |
| Adtralza (tralokinumab) | LEO Pharma Inc. | Negotiations were not pursued | Atopic dermatitis |
| Myinfla (colchicine) | Pendopharm, a division of Pharmascience Inc. | Negotiations were not pursued | Atherothrombotic Events in Coronary Artery Disease |
| Ngenla (somatrogon) | Pfizer Canada ULC | Concluded with an LOI | Growth hormone deficiency |
| Libtayo (cemiplimab) | Sanofi-Aventis Canada Inc. | Concluded without agreement | Basal cell carcinoma (BCC), locally advanced or metastatic, previously treated with a hedgehog pathway inhibitor |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma in adult patients (in combination with fluoropyrimidine- and platinum-containing chemotherapy) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic, in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients (First-line treatment) |
| Leqvio (inclisiran) | Novartis Pharmaceuticals Canada Inc. | Under consideration for negotiation | Primary hypercholesterolemia (non-familial and heterozygous familial) |
| Ultomiris (ravulizumab) | Alexion Pharma GmbH | Concluded with an LOI | Paroxysmal nocturnal hemoglobinuria (PNH) |
| Bijuva (estradiol and progesterone) | Knight Therapeutics Inc. | Concluded with an LOI | Vasomotor symptoms associated with menopause |
| Waymade-Trientine (trientine hydrochloride) | Waymade Canada Inc | Concluded with an LOI | Wilson's Disease |
| Vectibix (panitumumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Phesgo SC (perjeta and herceptin) | Hoffmann-La Roche Ltd. | Concluded without agreement | Metastatic breast cancer (HER2-positive) first-line treatment |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded with an LOI | Light chain amyloidosis (AL), newly diagnosed in adult patients (in combination with bortezomib, cyclophosphamide, and dexamethasone) |
| Trodelvy (sacituzumab govitecan) | Gilead Sciences Canada Inc. | Concluded with an LOI | Triple-negative breast cancer (mTNBC), unresectable locally advanced or metastatic, in adult patients who have received two or more prior therapies, at least one of them for metastatic disease |
| Sarclisa (Isatuximab) | Sanofi Genzyme Canada | Concluded with an LOI | Multiple myeloma, relapsed or refractory, in patients who have received 1 to 3 prior lines of therapy (in combination with carfilzomib and dexamethasone) |
| Piqray (alpelisib) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant) |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Esophageal or gastroesophageal junction cancer, completely resected, adjuvant treatment in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT) |
| Perjeta (pertuzumab) | Hoffmann-La Roche Ltd. | Concluded without agreement | Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy) |
| Increlex (mecasermin) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded with an LOI | Severe Primary Insulin-like Growth Factor-1 Deficiency |
| Dojolvi (triheptanoin) | Ultragenyx Canada Inc. | Concluded with an LOI | Long-Chain Fatty Acid Oxidation Disorders |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Herzuma (trastuzumab) | Teva Canada Ltd. | Concluded with an LOI | Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease |
| Imvexxy (estradiol) | Knight Therapeutics Inc. | Concluded with an LOI | Postmenopausal dyspareunia, moderate to severe |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-small cell lung cancer (NSCLC) adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, first-line treatment (in combination with ipilimumab and 2 cycles of platinum-based chemotherapy) |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Multiple Myeloma (including relapsed) |
| Padcev (enfortumab vedotin) | Seagen Canada Inc. | Concluded with an LOI | Unresectable, locally advanced or metastatic urothelial cancer in adult patients who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy |
| Ontruzant (trastuzumab) | Organon Canada Inc. | Concluded with an LOI | Metastatic breast cancer (HER2-positive) in patients with who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC) |
| Mvasi (bevacizumab) | Amgen Canada Inc. | Concluded with an LOI | Carcinoma of the colon or rectum, metastatic, first-line treatment in combination with fluoropyrimidine based chemotherapy or patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen |
| Opsynvi (macitentan and tadalafil) | Janssen Inc. | Concluded without agreement | Pulmonary Arterial Hypertension |
| Emgality (galcanezumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Migraine, prevention |
| Reblozyl (luspatercept) | Celgene Inc. | Concluded with an LOI | Myelodysplastic Syndromes Associated Anemia |
| Brukinsa (zanubrutinib) | BeiGene, Ltd. | Concluded with an LOI | Waldenström's Macroglobulinemia |
| Ledaga (chlormethine hydrochloride) | Recordati Rare Diseases Canada Inc. | Concluded without agreement | Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) |
| Evenity (romosozumab) | Amgen Canada Inc. | Concluded with an LOI | Osteoporosis |
| MAR-Trientine (trientine) | Marcan Pharmaceuticals Inc. | Concluded with an LOI | Wilson's Disease |
| Tukysa (tucatinib) | Seagen Canada Inc. | Concluded with an LOI | Breast cancer, locally advanced unresectable or metastatic, HER2-positive, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination (in combination with trastuzumab and capecitabine) |
| Abecma (idecabtagene vicleucel) | Celgene Inc. | Negotiations were not pursued | Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment. |
| Zaxine (rifaximin) | Lupin Pharma Canada Ltd. | Concluded with an LOI | Hepatic Encephalopathy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT |
| Aybintio (bevacizumab) | Organon Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma |
| Onureg (azacitidine) | Celgene Inc. | Concluded with an LOI | Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT) |
| Abrilada (adalimumab) | Pfizer Canada ULC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Yuflyma (adalimumab) | Celltrion Healthcare Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Kirsty (insulin aspart) | BGP Pharma ULC, d.b.a. Viatris Canada | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Givlaari (givosiran) | Alnylam Netherlands B.V. | Concluded with an LOI | Acute Hepatic Porphyria |
| Xeomin (incobotulinumtoxinA) | Merz Therapeutics Canada | Concluded without agreement | Chronic Sialorrhea associated with neurological disorders |
| Perseris (risperidone) | HLS Therapeutics Inc. | Concluded without agreement | Schizophrenia |
| Inqovi (decitabine-cedazuridine) | Taiho Pharma Canada Inc. | Concluded without agreement | Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients |
| Saxenda (liraglutide) | Novo Nordisk Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Vitrakvi (larotrectinib) | Bayer Inc. | Concluded with an LOI | Solid tumours in adult and pediatric patients that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options. |
| Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease (COPD) |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Vyxeos (daunorubicin and cytarabine) | Jazz Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences Canada Inc. | Concluded with an LOI | Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) |
| Evrysdi (risdiplam) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Spinal Muscular Atrophy |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Psoriatic Arthritis |
| Entuzity KwikPen (human insulin) | Eli Lilly Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Jorveza (budesonide) | AVIR Pharma Inc. | Concluded without agreement | Eosinophilic Esophagitis (Maintenance) |
| Venclexta (venetoclax) | AbbVie Corporation | Negotiations were not pursued | Acute myeloid leukemia (AML) Newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (In combination with low-dose cytarabine) |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Acute myeloid leukemia (AML) newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (in combination with azacitidine) |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Unresectable malignant pleural mesothelioma (MPM) in adult patients who have not received prior systemic therapy for MPM (in combination with ipilimumab) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), for first-line treatment of adult patients |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin) |
| Braftovi (encorafenib) | Pfizer Canada ULC | Concluded with an LOI | Metastatic colorectal cancer (mCRC) in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab) |
| Braftovi/Mektovi (encorfenib/binimetinib) | Pfizer Canada ULC | Concluded with an LOI | Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination) |
| Unituxin (dinutuximab) | United Therapeutics | Concluded with an LOI | High-risk Neuroblastoma in patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor |
| Inrebic (fedrantinib) | Celgene Inc. | Concluded with an LOI | Splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib |
| Zeposia (ozanimod) | Celgene Inc. | Negotiations were not pursued | Multiple Sclerosis, Relapsing-Remitting |
| Rybelsus (semaglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Tandem Diabetes Care Canada, Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Veltassa (patiromer) | Otsuka Canada Pharmaceutical Inc. | Concluded without agreement | Hyperkalemia |
| Reblozyl (luspatercept) | Celgene Inc. | Concluded with an LOI | Beta-Thalassemia Associated Anemia |
| Dupixent (dupilumab) | Sanofi Genzyme Canada | Concluded without agreement | Asthma |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in patients who have not received any prior anti-cancer therapy for metastatic disease |
| Ilumya (tildrakizumab) | Sun Pharma Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Simlandi (adalimumab) | Jamp Pharma Corporation | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Corzyna (ranolazine) | KYE Pharmaceuticals Inc. | Concluded without agreement | Angina Pectoris |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy |
| Odomzo (sonidegib) | Sun Pharma Canada Inc. | Negotiations were not pursued | Basal Cell Carcinoma (BCC), locally advanced in adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery |
| Bambevi (bevacizumab) | Apotex Inc. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma |
| Polivy (Polatuzumab Vedotin) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, in adult patients who are not eligible for autologous stem cell transplant & have received at least one prior therapy (In combination with bendamustine & rituximab) |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Concluded with an LOI | Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, previously untreated with an ALK inhibitor, in adult patients |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Metastatic Castration-Resistant Prostate Cancer and Deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM, monotherapy for the treatment of adult patients with mCRPC who have progressed following prior treatment with a NHA |
| Rozlytrek (Entrectinib) | Hoffmann-La Roche Ltd. | Concluded with an LOI | ROS1-positive Non-Small Cell Lung Cancer |
| Ruzurgi (Amifampridine) | Médunik Canada Inc. | Concluded without agreement | Lambert-Eaton Myasthenic Syndrome (LEMS) |
| Enspryng (satralizumab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Neuromyelitis optica spectrum disorder (NMOSD) |
| Osnuvo (teriparatide) | AVIR Pharma Inc. | Concluded with an LOI | Osteoporosis |
| Sarclisa (Isatuximab) | Sanofi Genzyme Canada | Concluded with an LOI | Multiple myeloma, relapsed and refractory, in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (in combination with pomalidomide and dexamethasone) |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Concluded without agreement | Rheumatoid Arthritis |
| Abevmy (bevacizumab) | BGP Pharma ULC | Concluded with an LOI | Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma |
| Bavencio (avelumab) | EMD Serono Canada, a division of EMD Inc. | Concluded with an LOI | Urothelial carcinoma (UC), first-line maintenance treatment of patients with locally advanced or metastatic whose disease has not progressed with first-line platinum-based induction chemotherapy |
| Ajovy (fremanezumab) | Teva Canada Ltd. | Concluded with an LOI | Prevention of Migraine in Adults |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Calquence (Acalabrutinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate |
| Calquence (Acalabrutinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Kynmobi (apomorphine hydrochloride) | Sunovion Pharmaceuticals Canada Inc. | Concluded with an LOI | Parkinson's disease |
| Kesimpta (ofatumumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Multiple Sclerosis, Relapsing-Remitting |
| Ofev (nintedanib) | Boehringer Ingelheim (Canada) Ltd. | Concluded with an LOI | Chronic fibrosing interstitial lung diseases |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Daurismo (Glasdegib) | Pfizer Canada ULC | Negotiations were not pursued | Acute Myeloid Leukemia (AML) |
| pdp-levETIRAcetam (levetiracetam) | Pendopharm, a division of Pharmascience Inc. | Concluded with an LOI | Epilepsy |
| Zolgensma (onasemnogene abeparvovec) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Tecentriq & Avastin (Atezolizumab & Bevacizumab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Forxiga (dapagliflozin) | AstraZeneca Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Crohn's disease |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible. |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides) |
| Spravato (esketamine hydrochloride) | Janssen Inc. | Negotiations were not pursued | Major Depressive Disorder |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL) |
| Riabni (rituximab) | Amgen Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Inclunox (enoxaparin) | Sandoz Canada Inc. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Noromby (enoxaparin) | Juno Pharmaceuticals Corp. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Nyvepria (pegfilgrastim) | Pfizer Canada ULC | Concluded with an LOI | Febrile neutropenia in non-myeloid malignancies |
| Trurapi (insulin aspart) | Sanofi-Aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Foquest (methylphenidate) | Elvium Life Sciences | Concluded with an LOI | Attention-deficit/hyperactivity disorder (ADHD) |
| Suboxone (film) (buprenorphine and naloxone) | Indivior UK Limited | Concluded with an LOI | Opioid Dependence |
| Atectura Breezhaler (indacaterol /mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Luxturna (voretigene neparvovec) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Vision loss, inherited retinal dystrophy |
| Hadlima (adalimumab) | Merck Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Idacio (adalimumab) | Fresenius Kabi Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hyrimoz (adalimumab) | Sandoz Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Amgevita (adalimumab) | Amgen Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hulio (adalimumab) | BGP Pharma ULC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Jorveza (budesonide) | AVIR Pharma Inc. | Concluded without agreement | Eosinophilic Esophagitis (Induction) |
| Duobrii (Halobetasol propionate and tazarotene) | Bausch Health, Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Nexplanon (etonogestrel) | Merck Canada Inc. | Concluded with an LOI | Prevention of Pregnancy |
| Soliris (eculizumab) | Alexion Pharma Canada Corp. | Concluded without agreement | Myasthenia Gravis |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration-Sensitive Prostate Cancer |
| Cablivi (caplacizumab) | Sanofi-Aventis Canada Inc. | Negotiations were not pursued | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| Rituxan SC (rituximab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Multiple Indications |
| Tecentriq & Avastin (Atezolizumab & Bevacizumab) | Hoffmann-La Roche Ltd. | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Aimovig (erenumab) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Migraine, Chronic |
| Vocabria and Cabenuva (cabotegravir and rilpivirine) | ViiV Healthcare | Concluded with an LOI | HIV-1 Infection |
| Mayzent (siponimod) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Secondary Progressive Multiple Sclerosis (SPMS) |
| Vascepa (icosapent ethyl) | HLS Therapeutics Inc. | Concluded with an LOI | Ischemic events in statin-treated patients |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Ulcerative Colitis |
| Soliris (eculizumab) | Alexion Pharma Canada Corp. | Concluded without agreement | Neuromyelitis optica spectrum disorder (NMOSD) |
| Darzalex SC (Daratumumab) | Janssen Inc. | Concluded without agreement | Multiple Myeloma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Peripheral T-cell Lymphoma (PTCL) |
| Cuvposa (Glycopyrrolate) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | Pediatric chronic severe drooling reduction (neurologic) |
| Xospata (Gilteritinib) | Astellas Pharma Inc. | Concluded with an LOI | Acute Myeloid Leukemia (AML) |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Ltd. | Concluded with an LOI | Asthma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Contrave (naltrexone hydrochloride and bupropion hydrochloride) | Bausch Health, Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Nubeqa (Darolutamide) | Bayer Inc. | Concluded with an LOI | Non-metastatic Castration-resistant prostate cancer |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | Metastatic Castration-Sensitive Prostate Cancer |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals Canada, Inc. | Concluded with an LOI | Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Crysvita (burosumab) | Kyowa Kirin Canada, Inc. | Concluded with an LOI | X-Linked Hypophosphatemia |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Dupixent (dupilumab) | Sanofi Genzyme Canada | Concluded with an LOI | Atopic dermatitis |
| Beovu (brolucizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Age-Related Macular Degeneration |
| Benlysta (belimumab) | GlaxoSmithKline Inc. | Concluded with an LOI | Systemic lupus erythematosus |
| Kisqali (with fulvestrant) (ribociclib with fulvestrant) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Allerject (epinephrine) | Kaleo Inc | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriatic Arthritis |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Avsola (infliximab) | Amgen Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis |
| Nivestym (filgrastim) | Pfizer Canada ULC | Concluded with an LOI | Neutropenia in various indications (Prevention or treatment) |
| Ziextenzo (pegfilgrastim) | Sandoz Canada Inc. | Concluded with an LOI | Febrile neutropenia in non-myeloid malignancies |
| Redesca (enoxaparin) | Valeo Pharma Inc. | Concluded with an LOI | Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer |
| Envarsus PA (tacrolimus) | Paladin Labs Inc. | Concluded with an LOI | Prophylaxis of Organ Rejection in Allogenic Kidney or Liver Transplant Adult Patients |
| Onstryv (safinamide) | Valeo Pharma Inc. | Concluded with an LOI | Parkinson's disease |
| Monoferric (iron (iii) isomaltoside 1000) | Pharmacosmos A/S | Concluded with an LOI | Iron Deficiency Anemia |
| Lokelma (sodium zirconium cyclosilicate) | AstraZeneca Canada Inc. | Negotiations were not pursued | Hyperkalemia |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded without agreement | Ankylosing spondylitis |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Concluded with an LOI | Transthyretin-mediated amyloidosis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Concluded with an LOI | Rheumatoid Arthritis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | Metastatic Gastric Cancer |
| Riximyo (rituximab) | Sandoz Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Ruxience (rituximab) | Pfizer Canada ULC | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded with an LOI | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Baqsimi (glucagon) | Eli Lilly Canada Inc. | Concluded with an LOI | Severe Hypoglycemia |
| Admelog (insulin lispro) | Sanofi-Aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Negotiations were not pursued | Non-Small Cell Lung Cancer (ALK+) |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Systemic Mastocytosis |
| Mylotarg (gemtuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Myeloid Leukemia (AML) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Renal Cell Carcinoma |
| Nerlynx (neratinib) | Knight Therapeutics Inc. | Negotiations were not pursued | Hormone Receptor-Positive Breast Cancer |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Takhzyro (lanadelumab) | Shire Pharma Canada ULC | Concluded with an LOI | Hereditary Angioedema |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Concluded with an LOI | Short Bowel Syndrome (SBS) |
| Verkazia (cyclosporine) | Santen Incorporated | Concluded with an LOI | Severe Vernal Keratoconjunctivitis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Mezera (mesalazine) | AVIR Pharma Inc. | Concluded with an LOI | Ulcerative Colitis |
| Kadcyla (trastuzumab emtansine) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Early Breast Cancer |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Squamous Non-Small Cell Lung Cancer |
| Tecentriq (atezolizumab) | Hoffmann-La Roche Ltd. | Concluded with an LOI | Extensive stage small cell lung cancer (ES-SCLC), first-line treatment, in combination with a platinum-based chemotherapy and etoposide |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Trintellix (vortioxetine) | Lundbeck Canada Inc. | Concluded with an LOI | Major Depressive Disorder |
| Xultophy (insulin degludec/liraglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Dovato (dolutegravir/lamivudine) | ViiV Healthcare | Concluded with an LOI | HIV-1 Infection |
| Iluvien (fluocinolone acetonide) | Knight Therapeutics Inc. | Negotiations were not pursued | Diabetic Macular Edema |
| Emerade (epinephrine bitartrate) | Bausch Health, Canada Inc. | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Olumiant (baricitinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Rheumatoid Arthritis |
| Orfadin Oral Suspension (nitisinone) | Sobi Canada Inc. | Concluded without agreement | Hereditary Tyrosinemia Type 1 |
| Onpattro (patisiran) | Alnylam Netherlands B.V. | Concluded with an LOI | Hereditary transthyretin-mediated amyloidosis |
| Tegsedi (inotersen) | Akcea Therapeutics Inc. | Concluded with an LOI | Hereditary transthyretin-mediated amyloidosis |
| Truxima (rituximab) | Teva Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Vitrakvi (larotrectinib) | Bayer Inc. | Negotiations were not pursued | Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours |
| Pomalyst (pomalidomide) | Celgene Inc. | Negotiations were not pursued | Multiple Myeloma (Relapsed) |
| Idhifa (enasidenib) | Celgene Inc. | Negotiations were not pursued | Acute Myeloid Leukemia (AML) |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Sublocade (buprenorphine) | Indivior UK Limited | Concluded with an LOI | Opioid Use Disorder |
| Cystadrops (cysteamine) | Recordati Rare Diseases Canada Inc. | Concluded with an LOI | Corneal cystine crystal deposits |
| Libtayo (cemiplimab) | Sanofi-Aventis Canada Inc. | Concluded with an LOI | Cutaneous Squamous Cell Carcinoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma (newly diagnosed) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded without agreement | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced or Metastatic Breast Cancer |
| Vizimpro (dacomitinib) | Pfizer Canada ULC | Concluded without agreement | Non-Squamous Non-Small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Negotiations were not pursued | Metastatic Urothelial Carcinoma (first line) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Venclexta/rituximab (venetoclax/rituximab) | AbbVie Corporation | Concluded with an LOI | In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | ROS1-positive advanced Non-Small Cell Lung Cancer |
| Ibrance/fulvestrant (palbociclib/fulvestrant) | Pfizer Canada ULC | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer |
| Herzuma (trastuzumab) | Teva Canada Ltd. | Concluded with an LOI | Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Concluded with an LOI | Pulmonary Arterial Hypertension |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded with an LOI | Secondary Prevention of Atherothrombotic Events |
| Triamcinolone Hexacetonide (triamcinolone hexacetonide) | Medexus Pharmaceuticals, Inc. | Concluded with an LOI | Rheumatoid Arthritis |
| Skyrizi (risankizumab) | AbbVie Corporation | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Vyzulta (latanoprostene bunod) | Bausch Health, Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
| Folotyn (pralatrexate) | Servier Canada Inc. | Concluded with an LOI | Peripheral T-cell Lymphoma (PTCL) |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded without agreement | Migraine, Chronic |
| Xermelo (telotristat) | Ipsen Biopharmaceuticals Canada, Inc. | Negotiations were not pursued | Carcinoid Syndrome |